SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains was marketed

COVID-19 Vaccine (Vero Cell), Inactivated—CoronaVac^® was officially listed in the WHO Emergency Use Listing on June 1, 2021

COVID-19 Vaccine CoronaVac^® has been approved for emergency use/conditional marketing in dozens of countries, including China, Chile, Turkey, Brazil, Indonesia, Etc.

Varicella Vaccine, Live, was marketed

Quadrivalent Influenza Vaccine was marketed

23-valent Pneumococcal Polysaccharide Vaccine was marketed

Initiated the "Anti-COVID-19 Action" program to R&D Inactivated COVID-19 vaccine, CoronaVac^®, which was one of the first vaccines against COVID-19 in China to be approved for emergency use

SINOVAC's fourth vaccine industrial base in Daxing, Beijing was put into use

Sinovac (Singapore) Ltd. was founded

Sinovac's Inactivated Hepatitis A vaccine, Healive^®, passed and the only passed in China the prequalification assessment by WHO

The world's first class I drug for preventative biological products was marketed- Enterovirus Type 71 Inactivated Vaccine (Vero Cell), Inlive^®

Mumps live Vaccine was marketed

Sinovac (Dalian) Vaccine Technology Co., Ltd. was founded

Acquired and started to build SINOVAC's third vaccine industrial base in Changping Beijing

The world's first H1N1 Influenza A Inactivated Vaccine (Split Virion), Inactivated, Panfu.1^®, was approved to produce for production and started massive vaccination in China

Along of Healive^® vaccine exported to Mongolia and Anflu^® vaccine exported to the Philippines, SINOVAC opened the international market

Sinovac Life Sciences Co., Ltd. was founded
Sinovac Holdings was moved to the NASDAQ Global Select Market

China's first Pandemic Influenza Vaccine (Inactivated, Adjuvanted), PanFlu^®,was approved to be produced for government stockpiling
Sinovac Biotech (Hong Kong) Ltd. was founded.

SINOVAC was the first company to join the IFPMA in developing countries

Anflu^®,  inactivated, Influenza Vaccine (Split Virion) was marketed

Bilive^®, China's first and the world's second Hepatitis A and Hepatitis B Combined Vaccine was marketed

The world's first SARS inactivated vaccine Phase I clinical study results was unblinded

Started study on pandemic influenza vaccine against human infection with highly pathogenic avian influenza (H5N1)
SINOVAC shares were listed on the American Stock Exchange (AMEX)

Started the development of an inactivated SARS Vaccine R&D program

Sinovac Holdings was listed on NASDAQ OTCBB in the United States through a reverse takeover

China's first inactivated Hepatitis A vaccine, Healive^®, was marketed

Sinovac Biotech Co., Ltd. was founded

A "new drug certificate" was obtained for the inactivated Hepatitis A vaccine

Cooperated with the National Institute for the Control of Pharmaceutical and Biological Products to initiate the development of an inactivated Hepatitis A vaccine

Developed China's first Hepatitis A enzyme-linked diagnostic reagent

Successfully isolated the TZ84 strain of the hepatitis A virus

Conducted an investigation into endemic areas with endemic hepatitis A